^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Next Generation Sequencing Analysis and its Benefit for Targeted Therapy of Lung Adenocarcinoma

Published date:
07/04/2023
Excerpt:
...patients with EML4-ALK fusion treated by alectinib was significantly favorable compared to patients without any targetable variant treated by chemotherapy (p=0.0172, p=0.0096, respectively).
DOI:
10.21873/cgp.20392
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Alectinib versus crizotinib in ALK-positive advanced non-small cell lung cancer and comparison of next-generation TKIs after crizotinib failure: Real-world evidence

Published date:
05/26/2022
Excerpt:
Patients with ALK-positive advanced NSCLC, who received crizotinib or alectinib treatment in first line, were retrospectively reviewed....Clinical outcomes have been comprehensively analyzed between TKIs, ALK fusions, EML4-ALK variants, and next-generation TKIs after crizotinib failure....Patients in EML4 group had a better prognosis than those in non-EML4 group after alectinib administration (HR 0.13, 95% CI: 0.03–0.60, p = 0.009)....Our results revealed alectinib had better PFS and higher intracranial efficacy compared to crizotinib in ALK-positive NSCLC, and might improve PFS by comparison with ceritinib and brigatinib after crizotinib failure.
DOI:
https://doi.org/10.1002/cam4.4834
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Special issue “The advance of solid tumor research in China”: Real-world clinical outcomes of alectinib for advanced non-small-cell lung cancer patients with ALK fusion in China

Published date:
05/17/2022
Excerpt:
Patients with advanced non-small-cell lung cancer (NSCLC) and EML4–ALK fusion were enrolled...The primary endpoints were objective response rate (ORR) and progression-free survival (PFS) to alectinib.…The 1- and 2-year PFS rates were 77.4% and 68.3%, respectively. ORR and disease control rate (DCR) were 53.5% and 91.3%, respectively.
DOI:
https://doi.org/10.1002/ijc.34123